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Abstract
Mood instability is a core clinical feature of affective and psychotic disorders. In keeping with the Research Domain
Criteria approach, it may be a useful construct for identifying biology that cuts across psychiatric categories. We aimed
to investigate the biological validity of a simple measure of mood instability and evaluate its genetic relationship with
several psychiatric disorders, including major depressive disorder (MDD), bipolar disorder (BD), schizophrenia, attention
deﬁcit hyperactivity disorder (ADHD), anxiety disorder and post-traumatic stress disorder (PTSD). We conducted a
genome-wide association study (GWAS) of mood instability in 53,525 cases and 60,443 controls from UK Biobank,
identifying four independently associated loci (on chromosomes 8, 9, 14 and 18), and a common single-nucleotide
polymorphism (SNP)-based heritability estimate of ~8%. We found a strong genetic correlation between mood
instability and MDD (rg = 0.60, SE = 0.07, p = 8.95 × 10
−17) and a small but signiﬁcant genetic correlation with both
schizophrenia (rg = 0.11, SE = 0.04, p = 0.01) and anxiety disorders (rg = 0.28, SE = 0.14, p = 0.04), although no genetic
correlation with BD, ADHD or PTSD was observed. Several genes at the associated loci may have a role in mood
instability, including the DCC netrin 1 receptor (DCC) gene, eukaryotic translation initiation factor 2B subunit beta (eIF2B2),
placental growth factor (PGF) and protein tyrosine phosphatase, receptor type D (PTPRD). Strengths of this study include
the very large sample size, but our measure of mood instability may be limited by the use of a single question. Overall,
this work suggests a polygenic basis for mood instability. This simple measure can be obtained in very large samples;
our ﬁndings suggest that doing so may offer the opportunity to illuminate the fundamental biology of mood
regulation.
Introduction
Mood instability is a common clinical feature of
affective and psychotic disorders, particularly major
depressive disorder (MDD), bipolar disorder (BD) and
schizophrenia1. It may also be relatively common in the
general population, estimated to affect ~13% of indivi-
duals2. As a dimensional psychopathological trait, it is
potentially a useful construct in line with the Research
Domain Criteria approach3. Mood instability may be of
fundamental importance for understanding the patho-
physiology of MDD and BD, as well as conditions such
as borderline personality disorder, anxiety disorders,
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attention deﬁcit hyperactivity disorder (ADHD) and psy-
chosis4. This trait is reported by 40–60% of individuals
with MDD5 and is recognised as part of the prodromal
stage of BD6. In established BD, it is a clinical feature that
independently predicts poor functional outcome7. Fur-
thermore, general population twin studies suggest that
additive genetic effects account for 40% of the variance in
measures of affect intensity and 25% of the variance in
affective liability8.
Population-based studies such as the Adult Psychiatric
Morbidity Survey (APMS) have deﬁned mood instability
based on responses to a single question, while clinical
studies have made use of more detailed rating scales4.
However, there is a lack of consensus about how best to
measure and classify mood instability, and none of the
currently available instruments adequately capture
intensity, speed and frequency of affective change, or
physiological and behavioural correlates. A recent sys-
tematic review proposed that mood instability be deﬁned
as 'rapid oscillations of intense affect, with a difﬁculty in
regulating these oscillations or their behavioural con-
sequences'9. Applying this deﬁnition will require the
future development and validation of a multidimensional
assessment of mood instability, which is currently not
available.
Within the UK Biobank population cohort of over 0.5
million individuals10, the baseline assessment interview
contained a question of relevance to mood instability,
speciﬁcally: 'Does your mood often goes up and down?'
This is similar to the question for mood instability used
within the APMS ('Do you have a lot of sudden mood
changes, suffered over the last several years'). Hypothe-
sising that this simple question taps into pathological
mood instability, we predicted that it would be more
commonly endorsed by individuals within UK Biobank
with MDD and BD, compared to individuals with no
psychiatric disorder. Moreover, under the hypothesis that
this trait has cross-disorder pathophysiological relevance,
we predicted that a genome-wide association study
(GWAS) might identify shared genetic liability to mood
instability and risk for psychiatric disorders in which
disordered mood is a feature, including MDD, BD, schi-
zophrenia, ADHD, anxiety disorder and post-traumatic
stress disorder (PTSD). Given the size of the sample, we
also aimed to identify loci associated with this measure of
mood instability.
Materials and methods
Sample
UK Biobank is a large cohort of more than 502,000
United Kingdom residents, aged between 40 and 69
years10. The aim of UK Biobank is to study the genetic,
environmental and lifestyle factors that cause or prevent
disease in middle and older age. Baseline assessments
occurred over a 4-year period, from 2006 to 2010, across
22 United Kingdom (UK) centres. These assessments
were comprehensive and included social, cognitive, life-
style and physical health measures. For the present study,
we used the ﬁrst genetic data release based on approxi-
mately one-third of UK Biobank participants. Aiming to
maximise homogeneity, we restricted the sample to those
who reported being of white UK ancestry (around 95% of
the sample).
UK Biobank obtained informed consent from all parti-
cipants, and this study was conducted under generic
approval from the NHS National Research Ethics Service
(approval letter dated 13 May 2016, Ref 16/NW/0274)
and under UK Biobank approvals for application #6553
'Genome-wide association studies of mental health' (PI
Daniel Smith).
Mood instability phenotype
As part of the baseline assessment, UK Biobank parti-
cipants completed the 12 items of the neuroticism scale
from the Eysenck Personality Questionnaire-Revised
Short Form (EPQ-R-S)11. One of these items assesses
mood instability, namely 'Does your mood often goes up
and down?' Participants responding ‘yes’ to this question
were considered to be cases of mood instability and those
responding ‘no’ were considered controls. From the
control sample, we excluded those who reported being on
psychotropic medication, and those who reported a phy-
sician diagnosis of psychiatric disorder (including MDD,
BD, anxiety/panic attacks, ‘nervous breakdown’, schizo-
phrenia and deliberate self-harm/suicide attempt).
After quality-control steps (detailed below) and exclu-
sions (3679 participants responded ‘don’t know’ and 211
responded ‘prefer not to say’), the ﬁnal sample for genetic
analysis comprised 53,525 cases of mood instability and
60,443 controls. Mood instability cases were younger than
controls (mean age 55.8 years (SD= 8.05) vs. 57.7 years
(SD= 7.74); p< 0.0001) and had a greater proportion of
females (55.5% vs. 49.6%; p< 0.0001).
Genotyping and imputation
In June 2015, UK Biobank released the ﬁrst set of
genotypic data for 152,729 UK Biobank participants.
Approximately 67% of this sample was genotyped using
the Affymetrix UK Biobank Axiom array (Santa Clara,
CA, USA) and the remaining 33% were genotyped using
the Affymetrix UK BiLEVE Axiom array. These arrays
have over 95% content in common. Only autosomal data
were available under the data release. Data were pre-
imputed by UK Biobank as fully described in the UK
Biobank interim release documentation12. Brieﬂy, after
removing genotyped single-nucleotide polymorphisms
(SNPs) that were outliers, or were multiallelic or of low
frequency (minor allele frequency (MAF)< 1%), phasing
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was performed using a modiﬁed version of SHAPEIT2
and imputation was carried out using IMPUTE2 algo-
rithms, as implemented in a C++ platform for compu-
tational efﬁciency13, 14. Imputation was based upon a
merged reference panel of 87,696,888 biallelic variants on
12,570 haplotypes constituted from the 1000 Genomes
Phase 3 and UK10K haplotype panels15. Variants with
MAF< 0.001% were excluded from the imputed marker
set. Stringent quality control before release was applied by
the Wellcome Trust Centre for Human Genetics, as
described in UK Biobank documentation16.
Statistical analyses
Quality control and association analyses
Before all analyses, further quality-control measures
were applied. Individuals were removed based on UK
Biobank genomic analysis exclusions (Biobank Data Dic-
tionary item #22010), relatedness (#22012: genetic relat-
edness factor; a random member of each set of individuals
with KING-estimated kinship coefﬁcient >0.0442 was
removed), gender mismatch (#22001: genetic sex),
ancestry (#22006: ethnic grouping; principal component
(PC) analysis identiﬁed probable Caucasians within those
individuals who were self-identiﬁed as British and other
individuals were removed from the analysis), and quality-
control failure in the UK BiLEVE study (#22050: UK
BiLEVE Affymetrix quality control for samples and
#22051: UK BiLEVE genotype quality control for sam-
ples). A sample of 113,968 individuals remained for fur-
ther analyses. Of these, 53,525 were classed as cases and
60,443 were classiﬁed as controls. Genotype data were
further ﬁltered by removal of SNPs with Hardy–Weinberg
equilibrium P< 10−6, with MAF< 0.01, with imputation
quality score <0.4 and with data on <90% of the sample
after excluding genotype calls made with <90% posterior
probability, after which 8,797,848 variants were retained.
Association analysis was conducted in PLINK17 using
logistic regression under a model of additive allelic effects
with sex, age, genotyping array and the ﬁrst eight PCs
(Biobank Data Dictionary items #22009.01 to #22009.08)
as covariates. Sex and age were included as covariates
because cases and controls differed signiﬁcantly on these
measures. Genetic PCs were included to control for hid-
den population structure within the sample, and the ﬁrst
eight PCs, out of 15 available in the Biobank, were
selected after visual inspection of each pair of PCs, taking
forward only those that resulted in multiple clusters of
individuals after excluding individuals self-reporting as
being of non-white British ancestry (Biobank Data Dic-
tionary item #22006). Overall, population structure had
little impact on mood instability status. The threshold for
genome-wide signiﬁcance was p< 5.0× 10−8.
Heritability and genetic correlation between mood instability
and psychiatric phenotypes
We applied Linkage Disequilibrium Score Regression
(LDSR)18 to the GWAS summary statistics to estimate
SNP heritability (h2SNP). Genetic correlations between
mood instability and MDD, BD, schizophrenia, ADHD,
anxiety disorder and PTSD were also evaluated using
LDSR19 (with unconstrained intercept), a process that
corrects for potential sample overlap without relying on
the availability of individual genotypes18. For the MDD,
BD, schizophrenia, ADHD, anxiety disorder and PTSD
phenotypes, we used GWAS summary statistics provided
by the Psychiatric Genomics Consortium (http://www.
med.unc.edu/pgc/)20–25. Note that for the purposes of
these genetic correlation analyses we re-ran the GWAS of
mood instability excluding from the cases those 9865
participants who reported being on psychotropic medi-
cation, or who self-reported psychiatric disorder (MDD,
BD, anxiety/panic attacks, ‘nervous breakdown’, schizo-
phrenia and deliberate self-harm/suicide attempt). This
secondary GWAS output (rather than the primary GWAS
reported below) was used for the genetic correlation cal-
culations and for polygenic risk score (PRS) analyses, the
rationale being that this was a more conservative
approach that would avoid genetic correlations between
mood instability and MDD/BD/schizophrenia/ADHD/
anxiety disorders/PTSD being driven by a subset of
individuals with psychiatric disorder.
PRS analysis of MDD, BD and schizophrenia as predictors of
mood instability
PRSs were created using the output of the PCG MDD
29 of 32 cohort GWAS (supplied by the MDD working
group of the PGC, http://www.med.unc.edu/pgc/pgc-
workgroups), BD GWAS20 and schizophrenia GWAS21.
Five PRS were created for each psychiatric phenotype
using p value cutoffs of p< 5× 10−8, p< 0.01, p< 0.05, p
< 0.1 and p< 0.5, with the exception of MDD for which
there were no genome-wide signiﬁcant SNPs. Ambiguous
SNPs, indels (insertion/deletion mutations) and SNPs
with an imputation quality score of less than 0.8 were
removed. LD clumping was performed via PLINK on a
random sample of 10,000 individuals using an r2> 0.05 in
a 250 kb window. SNPs were clumped into sets and ﬁl-
tered, selecting the SNP with the lowest p value from each
set. In the event that two or more SNPs from a set had the
same p value, the SNP with the largest beta coefﬁcient was
used. PLINK was also used to calculate the PRS to pro-
duce a per-allele weighted score with no mean
imputation.
PRS modelling
Only those subjects who were used for the genetic
correlation analyses were used in the PRS analyses (that is,
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PRS analyses also excluded from both case and control
groups those individuals in UK Biobank with psychiatric
disorder). Modelling was performed in R (version 3.1.2)
using the glm function. Full sample and age-stratiﬁed
analysis models were adjusted for age, sex, chip and PGCs
1–8, whereas sex-stratiﬁed analysis was not adjusted for
sex. Scores were then split into deciles using the ntile
function of the dplyr package. Model Nagelkerke r2 was
calculated using the fmsb package.
Results
Mood instability in MDD and BD within UK Biobank
In previous work we have identiﬁed individuals within
UK Biobank with a probable diagnosis of mood disorder,
including cases of MDD (subdivided into single-episode
MDD, recurrent moderate MDD and recurrent severe
MDD) and BD, as well as non-mood disordered con-
trols26. These classiﬁcations were independent of
response to the mood instability question or other ques-
tions from the EPQ-R-S. For the group of participants
who could be classiﬁed in this way, we assessed the pro-
portion with mood instability within each mood disorder
category. All mood disorder groups had a signiﬁcantly
greater proportion of individuals with mood instability
compared with the control group (Table 1), in which the
prevalence was 35.3%. This proportion was highest in the
BD group (74.0%) followed by the three MDD groups
(71.7% for recurrent severe MDD, 64.2% for recurrent
moderate MDD and 43.7% for single-episode MDD).
There were too few UK Biobank participants with a reli-
able classiﬁcation of schizophrenia, ADHD, anxiety dis-
order or PTSD to allow for an assessment of the
prevalence of mood instability in these groups.
GWAS of mood instability
The mood instability GWAS results are summarised in
Fig. 1 (Manhattan plot), Fig. 2 (QQ plot) and Table 2
(genome-wide signiﬁcant loci associated with mood
instability). Regional plots are provided in Figs. 3a–d.
Overall, the GWAS data showed modest deviation in
the test statistics compared with the null (λGC= 1.13); this
was negligible in the context of sample size (λGC 1000=
1.002). LDSR suggested that deviation from the null was
due to a polygenic architecture in which h2SNP accounted
for ~8% of the population variance in mood instability
(observed scale h2SNP= 0.077 (SE 0.007)), rather than
inﬂation due to unconstrained population structure (LD
regression intercept= 0.998 (SE 0.009)).
We observed four independent genomic loci exhibiting
genome-wide signiﬁcant associations with mood
instability (Fig. 1, Table 2 and Figs. 3a–d), on chromosome
8 (index SNP rs7829975; CLDN23 and MFHAS1), chro-
mosome 9 (index SNP rs10959826; PTPRD), chromosome
14 (index SNP rs397852991; LTBP2, AREL1, FCF1,
YLPM1, PROX2, DLST, RPS6KL1, PGF, EIF2B2 and
MLH3) and chromosome 18 (index SNP rs8084280;
DCC). In total, there were 111 genome-wide signiﬁcant
Table 1 Proportion of individuals with mood instability
within mood disorder groups, compared to non-mood
disordered controls
Mood instability
N (%)
Pearson Χ2 P value
BD 1180 (74.0) 1.0 × 103 <0.001
Recurrent MDD, severe 6303 (71.7) 4.5 × 103 <0.001
Recurrent MDD,
moderate
9509 (64.2) 4.4 × 103 <0.001
Single-episode MDD 3403 (43.7) 221.1 <0.001
Non-mood disordered
controls
30,844 (35.3) – –
BD bipolar disorder, MDD major depressive disorder
Fig. 1 Manhattan plot of GWAS of mood instability in UK Biobank (n =
113,968)
Fig. 2 QQ plot for UK Biobank mood instability GWAS results
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SNPs across all loci. Given the functional alleles that drive
association signals in GWAS may not affect the nearest
gene, we use the above gene names to provide a guide to
location rather than to imply that altered function or
expression of those genes are the sources of the associa-
tion signals.
We also repeated this GWAS for males and females
separately (Supplementary Figs. S1 and S2) and for the
sample stratiﬁed according to median age (age 58 and
below, and age 59 and above; Supplementary Figs. S3 and
S4). No genome-wide signiﬁcant loci were observed from
these stratiﬁed analyses, possibly because of reduced
power, apart from the retention of a single genome-wide
signiﬁcant ﬁnding at rs8084280 on chromosome 18 (the
DCC gene) for males only (Supplementary Fig. S1). There
was a high degree of genetic correlation between mood
instability in males and females (rg= 1.02, SE= 0.09, p=
2.84× 10−30), and between mood instability in the
younger and older subgroups (rg= 1.02, SE= 0.09, p=
2.67× 10−27).
Within supplementary materials, we also present the
results of the secondary GWAS of mood instability that
was excluded from the case group of 9865 participants
with a psychiatric disorder (Supplementary Table S1).
This GWAS was used to assess for genetic correlation
between mood instability and MDD, BD, schizophrenia,
ADHD, anxiety disorders and PTSD, and for the PRS
analyses. Supplementary Table S1 shows that the risk
allele frequencies (RAFs) of the index SNPs within the
four genome-wide signiﬁcant loci from the primary
GWAS were very similar to the RAFs for these same
SNPs within this secondary GWAS: for rs7829975 the
RAF was 0.516 vs. 0.523; for rs10959826 it was 0.785 vs.
0.789; for rs397852991 it was 0.606 vs. 0.673; and for
rs8084280 it was 0.508 vs. 0.514). However, it should
be noted that, perhaps due to a loss of power from
excluding 9865 individuals, only one of these four loci
retained genome-wide signiﬁcance (rs7829975 on chro-
mosome 8).
Genetic correlation of mood instability with MDD,
schizophrenia, BD, ADHD, anxiety disorder and PTSD
We identiﬁed strong genetic correlation between mood
instability and MDD (rg= 0.60, SE= 0.07, p= 8.95×
10−17) and a smaller, but signiﬁcant, correlation between
mood instability and both schizophrenia (rg= 0.11, SE=
0.04, p= 0.01) and anxiety disorders (rg= 0.28, SE= 0.14,
p= 0.04; Table 3). We did not ﬁnd signiﬁcant genetic
overlap between mood instability and BD (rg= 0.01, SE=
0.05, p= 0.27), ADHD (rg= 0.14, SE= 0.11, p= 0.18) or
PTSD (rg= 0.33, SE= 0.17, p= 0.06).
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Fig. 3 Regional plots of the four genome-wide signiﬁcant mood instability loci. a Chromosome 8 region 8.5–8.8 MB. b Chromosome 9 region 10–12
MB. c Chromosome 14 region 75–75.5 MB. d Chromosome 18 region 50.5–51 MB
Table 3 Genetic correlation between mood instability and MDD, schizophrenia, BD, PTSD, ADHD and anxiety disorder
Phenotype Rg se z p h2 obs h2 obs se h2 int h2 int se Gcov int Gcov int se
MDD 0.6 0.07 8.32 8.95 × 10−17 0.11 0.01 0.99 0.008 −0.0019 0.006
Schizophrenia 0.11 0.04 2.48 0.01 0.25 0.01 1.03 0.01 0.0008 0.007
BD 0.01 0.05 0.27 0.27 0.12 0.01 1.02 0.008 0.0069 0.005
PTSD 0.33 0.17 1.9 0.06 0.10 0.004 0.99 0.007 0.0004 0.005
ADHD 0.14 0.11 1.35 0.18 0.4 0.15 1.01 0.01 0.0046 0.004
Anxiety disorder 0.28 0.14 2.04 0.04 0.06 0.03 1.00 0.01 0.01 0.005
Rg genetic correlation with mood instability, SE standard error of the genetic correlation, Z the test statistic, h
2 obs heritability on the observed scale, h2 obs SE the
standard error of the heritability, h2 int intercept of the heritability, h2 int SE standard error of the heritability intercept, Gcov int intercept of the genetic covariance,
Gcov int SE standard error of the genetic covariance intercept, MDD major depressive disorder, BD bipolar disorder, PTSD post-traumatic stress disorder, ADHD
attention deﬁcit hyperactivity disorder
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PRS analysis of MDD, BD and schizophrenia as predictors
of mood instability
Using the PRS approach, both MDD and schizophrenia
had signiﬁcant positive correlations with mood instability
status (for MDD at p< 0.5 PRS threshold: OR= 1.029,
95% CI= 1.02–1.033, r2= 0.023, p= 1.00× 10−34 and for
schizophrenia at p< 0.1 PRS threshold: OR= 1.009, 95%
CI= 1.005–1.014, r2= 0.021, p= 6.71× 10−5; Supple-
mentary Table S2). There was no evidence of an asso-
ciation between PRS for BD and mood instability. This
ﬁnding of a positive correlation between PRSs for MDD
and schizophrenia and mood instability status (and no
such correlation for BD PRS) was consistent across
additional analyses stratiﬁed for sex and age (Supple-
mentary Tables S3–S6).
Discussion
We have identiﬁed four independent loci associated
with mood instability within a large population cohort, in
what is to date the only GWAS of this phenotype. We also
identiﬁed a SNP-based heritability estimate for mood
instability of ~8%, and a strong genetic correlation
between mood instability and MDD, suggesting sub-
stantial genetic overlap between mood instability and
vulnerability to MDD. There was also a small but sig-
niﬁcant genetic correlation between mood instability and
schizophrenia and between mood instability and anxiety
disorders, but no signiﬁcant genetic correlation with BD,
ADHD or PTSD. PRS analyses found a positive correla-
tion between genes for both MDD and schizophrenia and
mood instability status, but this was not the case for BD.
The strong genetic correlation between mood instability
and MDD is of interest because it is consistent with the
hypothesis that at least part of the pathophysiology of
MDD might include a reduced capacity to effectively
regulate affective states. In support of this is evidence that
individuals with MDD tend to have maladaptive responses
to intense emotions, responding with worry, rumination
and self-criticism, which can then exacerbate negative
emotional states27. This maladaptive pattern of responses
is also consistent with our ﬁnding of a small but sig-
niﬁcant genetic correlation between mood instability and
both anxiety disorder and schizophrenia.
The lack of genetic correlation between mood instability
and BD was unexpected, given that mood instability is
considered a core deﬁcit in BD4 and was more common in
our BD cases than MDD cases. Similarly, a genetic cor-
relation between mood instability, ADHD and PTSD
might have been anticipated. This lack of correlation
between mood instability and BD/ADHD/PTSD is difﬁ-
cult to account for, but might be explained by the rela-
tively underpowered nature of the BD, ADHD and PTSD
GWAS analyses, compared to the analyses used for MDD
and schizophrenia. It is worth noting that, although not
signiﬁcant, the magnitude of the genetic correlation
between mood instability and ADHD was 0.14. Similarly,
the genetic correlation between mood instability and
PTSD was not signiﬁcant but had a magnitude of 0.33.
It is well documented that MDD occurs more com-
monly in females than in males, and it is possible that
mood instability may be of greater relevance as a cross-
cutting phenotype for women compared to men. We
therefore carried out a GWAS of mood instability for
males and females separately (Supplementary Fig. S1 and
Fig. S2). These stratiﬁed analyses found no genome-wide
signiﬁcant loci for females and only one genome-wide
signiﬁcant locus for males (the previously identiﬁed locus
on chromosome 18). Furthermore, there was perfect
genetic correlation between mood instability in males and
females. Although these analyses had reduced power, they
suggest that there was no evidence for a large number of
sex-speciﬁc loci for mood instability. Similarly, we carried
out GWAS stratiﬁed by age, for those in the sample at or
below the median age of 58 and for those above age 58
(Supplementary Figs. S3 and S4). As with stratiﬁcation by
sex, these age-stratiﬁed analyses did not identify any
genome-wide signiﬁcant loci, and there was perfect cor-
relation between mood instability in the younger and
older subgroups.
It is not possible to be certain which of the genes within
associated loci are likely to be most relevant to the
pathophysiology of mood instability but several genes of
interest were identiﬁed. For example, the lead SNP within
the associated region on chromosome 18 lies in intron 9
of the DCC netrin 1 receptor (originally named deleted in
colorectal cancer; DCC) gene, with no other protein-
coding genes for >500 kb on either side (Fig. 3d). DCC is
the receptor for the guidance cue netrin 1, which has a
central role in the development of the nervous system,
including (but not limited to) the organisation and func-
tion of mesocorticolimbic dopamine systems28. Recent
studies have shown a range of human phenotypes asso-
ciated with loss-of-function mutations in DCC, including
agenesis of the corpus callosum, learning disabilities and
mirror movements, all associated with a large-scale dis-
ruption of the development of commissural connectivity
and lateralisation29, 30. Manitt et al. have identiﬁed that
DCC has a role in regulating the connectivity of the
medial prefrontal cortex during adolescence and found
that DCC expression was elevated in the brain tissue of
antidepressant-free subjects who committed suicide31.
This suggests a possible role for DCC variants in
increasing predisposition to mood instability and mood
disorders, as well as related psychopathological
phenotypes.
The associated region on chromosome 14 contains at
least 10 candidate genes (Table 2 and Fig. 3c). One of
these is translation initiation factor 2B subunit beta
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(EIF2B2), mutations in which are known to cause a range
of clinically heterogeneous leukodystrophies32. Reduced
white matter integrity has been consistently associated
with negative emotionality traits (such as harm avoidance,
neuroticism and trait anxiety)33, as well as with MDD and
BD34. It is therefore possible that variation in EIF2B2 may
have a role in mood instability.
Another gene within the associated region on chro-
mosome 14 is placental growth factor (PGF), a member of
the angiogenic vascular endothelial growth factor (VEGF)
family35, 36, which is expressed at high levels in the pla-
centa and thyroid37. PGF has a wide range of functions,
including embryonic thyroid development38 and immune
system function39, 40, as well as a role in atherosclerosis,
angiogenesis in cancer, cutaneous delayed-type hyper-
sensitivity, obesity, rheumatoid arthritis and pre-
eclampsia39, 41–44. PGF may be of interest because of the
long-established association between thyroid dysfunction
and both MDD and BD45, along with the recent obser-
vation that pre-eclampsia may be a marker for the sub-
sequent development of mood disorders46.
Also of interest is the ﬁnding that the gene for protein
tyrosine phosphatase, receptor type D (PTPRD) lies within
1Mb of the associated region on chromosome 9 (Fig. 3b).
PTPRD encodes a receptor type protein tyrosine phos-
phatase known to be expressed in the brain and with an
organising role at a variety of synapses, including those
that play a role in synaptic plasticity47. As such, it may
have a role in a broad range of psychopathology.
Two of the genomic loci associated with mood
instability (on chromosomes eight and nine) overlap with
loci found to be associated with neuroticism in a recent
GWAS and meta-analysis, which combined data from the
UK Biobank cohort, the Generation Scotland cohort and a
cohort from the Queensland Institute of Medical
Research48. The neuroticism study made use of scores on
the 12-item EPQ-R-S questionnaire, of which one of the
questions was the mood instability question used in the
present study. This overlap in ﬁndings suggests that mood
instability is a key component of neuroticism as deﬁned
by the EPQ-R-S and that at least some of the gene variants
implicated in mood instability are likely to contribute to
the broader phenotype of neuroticism. We did not assess
for genetic correlation between mood instability and
neuroticism using LDSR because both GWAS outputs
were predominantly from the same UK Biobank sample.
Strengths and limitations
To the best of our knowledge, this is the ﬁrst reported
GWAS of mood instability. It has enabled objective esti-
mates of heritability and genetic correlation with important
psychiatric disorders to be made for the ﬁrst time. In the
future, genotyping data for the full UK Biobank sample
(502,000 participants) will be available. This increased
sample size may identify larger estimates of shared variance
between mood instability and psychiatric disorders.
Some important limitations of this work are acknowl-
edged. The mood instability phenotype used was based on
response to a single-item question ('Does your mood often
goes up and down?'), which may be an imperfect measure
of mood instability. Approximately 44% of the whole UK
Biobank cohort answered ‘yes’ to this question, a much
larger proportion than the 13% of participants classiﬁed as
having mood instability within the UK APMS2. This may
be because the assessment of mood instability in the
APMS was based on a slightly different question ('Do you
have a lot of sudden mood changes') and because
respondents had to additionally report that they 'suffered
this symptom over the last several years'. Clearly, a
potential limitation of self-report is the possibility of
responder bias and, further, a more complete and objec-
tively assessed measure of mood instability would have
been preferable. However, this was not available to us in
the UK Biobank phenotype data set and is unlikely to be
feasible to collect within a population cohort of this size.
Conclusions
Despite a recognition that mood instability is likely to be
an important phenotype underpinning a range of psychiatric
disorders—particularly mood disorders4—there has to date
been very little work on its neural correlates. Early investi-
gations tentatively suggest a role for altered function and/or
connectivity of the amygdala49, but this is an area that is
currently underdeveloped. It is hoped that our ﬁndings will
stimulate new research on mood instability, which may be a
clinically useful and biologically valid trait that cuts across
traditional diagnostic categories50.
Acknowledgements
This research was conducted using the UK Biobank resource. UK Biobank was
established by the Wellcome Trust, Medical Research Council, Department of
Health, Scottish Government and Northwest Regional Development Agency.
UK Biobank has also had funding from the Welsh Assembly Government and
the British Heart Foundation. Data collection was funded by UK Biobank. J.W. is
supported by the JMAS Sim Fellowship for depression research from the Royal
College of Physicians of Edinburgh (173558). D.J.S. is supported by an
Independent Investigator Award from the Brain and Behaviour Research
Foundation (21930) and a Lister Prize Fellowship (173096). A.F. is supported by
an MRC Doctoral Training Programme Studentship at the University of
Glasgow (MR/K501335/1). The work at Cardiff University was funded by
Medical Research Council (MRC) Centre (G0800509) and Programme Grants
(G0801418). The funders had no role in the design or analysis of this study,
decision to publish or preparation of the manuscript.
Author details
1Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK.
2Department of Medicine Solna, Karolinska Institute, Stockholm, Sweden.
3School of Life Sciences, College of Medical, Veterinary and Life Sciences,
University of Glasgow, Glasgow, UK. 4MRC Centre for Neuropsychiatric Genetics
and Genomics, Cardiff University, Cardiff, UK
Competing interests
The authors declare no competing interests.
Ward et al. Translational Psychiatry  (2017) 7:1264 Page 8 of 9
Translational Psychiatry
Publisher's note: Springer Nature remains neutral with regard to jurisdictional
claims in published maps and institutional afﬁliations.
Supplementary information
The online version of this article (doi:10.1038/s41398-017-0012-7) contains
supplementary material.
Received: 7 April 2017 Revised: 9 June 2017 Accepted: 9 August 2017
References
1. Balbuena, L., Bowen, R., Baetz, M. & Marwaha, S. Mood instability and irritability
as core symptoms of major depression: an exploration using rasch analysis.
Front. Psychiatry 7, 174 (2016).
2. Marwaha, S., Parsons, N., Flanagan, S. & Broome, M. The prevalence and clinical
associations of mood instability in adults living in England: results from the
adult psychiatric morbidity survey 2007. Psychiatr. Res. 205, 262–268 (2013).
3. Cuthbert, B. & Insel, T. Toward the future of psychiatric diagnosis: the seven
pillars of RDoC. BMC Med. 11, 126 (2013).
4. Broome, M. R., Saunders, K. E. A., Harrison, P. J. & Marwaha, S. Mood instability:
signiﬁcance, deﬁnition and measurement. Br. J. Psychiatry 207, 283–285 (2015).
5. Marwaha, S. et al. Affective instability, childhood trauma and major affective
disorders. J. Affect. Disord. 190, 764–771 (2016).
6. Howes, O. D. et al. A comprehensive review and model of putative prodromal
features of bipolar affective disorder. Psychol. Med. 41, 1567–1577 (2011).
7. Strejilevich, S. A. et al. Mood instability and functional recovery in bipolar
disorders. Acta Psychiatr. Scand. 128, 194–202 (2013).
8. Coccaro, E. F., Ong, A. D., Seroczynski, A. D. & Bergeman, C. S. Affective intensity
and lability: heritability in adult male twins. J. Affect. Disord. 136, 1011–1016
(2012).
9. Marwaha, S. et al. How is affective instability deﬁned and measured? A sys-
tematic review. Psychol. Med. 44, 1793–1808 (2014).
10. Sudlow, C. et al. UK Biobank: an open access resource for identifying the
causes of a wide range of complex diseases of middle and old age. PLoS Med.
12, e1001779 (2015).
11. Eysenck, S. B. G., Eysenck, H. J. & Barrett, P. A revised version of the psycho-
ticism scale. Pers. Individ. Dif. 6, 21–29 (1985).
12. UK Biobank. Genotype imputation and genetic association studies of UK
Biobank, Interim Data Release, 11 September 2015; http://www.ukbiobank.ac.
uk/wp-content/uploads/2014/04/imputation_documentation_May2015.pdf.
13. Delaneau, O., Zagury, J.-F. & Marchini, J. Improved whole-chromosome
phasing for disease and population genetic studies. Nat. Method 10, 5–6
(2013).
14. Howie, B., Marchini, J. & Stephens, M. Genotype imputation with thousands of
genomes. G3 1, 457 (2011).
15. Huang, J. et al. Improved imputation of low-frequency and rare variants using
the UK10K haplotype reference panel. Nat. Commun. 6, 8111 (2015).
16. UK Biobank. Genotyping of 500,000 UK Biobank participants. Description
of sample processing workﬂow and preparation of DNA for genotyping,
11 September 2015; https://biobank.ctsu.ox.ac.uk/crystal/docs/genotyping_
sample_workﬂow.pdf.
17. Purcell S. et al. PLINK: A Tool Set for whole-genome association and
population-based linkage analyses. Am. J. Hum. Genet. 81, 559–575 (2007).
18. Bulik-Sullivan, B. K. et al. LD Score regression distinguishes confounding from
polygenicity in genome-wide association studies. Nat. Genet. 47, 291–295
(2015).
19. Bulik-Sullivan, B. et al. An atlas of genetic correlations across human diseases
and traits. Nat. Genet. 47, 1236–1241 (2015).
20. Bipolar Disorder Working Group of the Psychiatric Genomics Consortium.
Large-scale genome-wide association analysis of bipolar disorder identiﬁes a
new susceptibility locus near ODZ4. Nat. Genet. 43, 977–983 (2011).
21. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Bio-
logical insights from 108 schizophrenia-associated genetic loci. Nature 511,
421–427 (2014).
22. Major Depressive Disorder Working Group of the Psychiatric Genomics Con-
sortium. A mega-analysis of genome-wide association studies for major
depressive disorder. Mol. Psychiatry 18, 497–511 (2013).
23. Neale, B. M. et al. Meta-analysis of genome-wide association studies of
attention-deﬁcit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 49,
884–897 (2010).
24. Otowa, T. et al. Meta-analysis of genome-wide association studies of anxiety
disorders. Mol. Psychiatry 21, 1391–1399 (2016).
25. Duncan, L. E. et al. Largest GWAS of PTSD (N = 20[thinsp]070) yields genetic
overlap with schizophrenia and sex differences in heritability. Mol. Psychiatry
(2017).
26. Smith, D. J. et al. Prevalence and characteristics of probable major depression
and bipolar disorder within UK Biobank: cross-sectional study of 172,751
participants. PLoS ONE 8, e75362 (2013).
27. Mennin, D. S. & Fresco, D. M. What, me worry and ruminate about DSM-5 and
RDoC? The importance of targeting negative self-referential processing. Clin.
Psychol. 20, 258–267 (2013).
28. Manitt, C. et al. The Netrin receptor DCC is required in the pubertal organi-
zation of mesocortical dopamine circuitry. J. Neurosci. 31, 8381–8394 (2011).
29. Jamuar, S. S. et al. Biallelic mutations in human DCC cause developmental
split-brain syndrome. Nat. Genet. 49, 606–612 (2017).
30. Marsh, A. P. L. et al. Mutations in DCC cause isolated agenesis of the corpus
callosum with incomplete penetrance. Nat. Genet. 49, 511–514 (2017).
31. Manitt, C. et al. dcc orchestrates the development of the prefrontal cortex
during adolescence and is altered in psychiatric patients. Transl. Psychiatry 3,
e338 (2013).
32. Horzinski, L. et al. Eukaryotic initiation factor 2B (eIF2B) GEF activity as a
diagnostic tool for EIF2B-related disorders. PLoS ONE 4, e8318 (2009).
33. Mincic, A. M. Neuroanatomical correlates of negative emotionality-related
traits: a systematic review and meta-analysis. Neuropsychologia 77, 97–118
(2015).
34. Sexton, C. E., Mackay, C. E. & Ebmeier, K. P. A systematic review of diffusion
tensor imaging studies in affective disorders. Biol. Psychiatry 66, 814–823
(2009).
35. De Falco, S. The discovery of placenta growth factor and its biological activity.
Exp. Mol. Med. 44, 1–9 (2012).
36. Xie, T. et al. VEGF-related polymorphisms identiﬁed by GWAS and risk for
major depression. Transl. Psychiatry 7, e1055 (2017).
37. Viglietto, G. et al. Upregulation of vascular endothelial growth factor (VEGF)
and downregulation of placenta growth factor (PlGF) associated with
malignancy in human thyroid tumors and cell lines. Oncogene 11, 1569–1579
(1995).
38. Korevaar, T. I. et al. Soluble Flt1 and placental growth factor are novel
determinants of newborn thyroid (dys)function: the generation R study. J. Clin.
Endocrinol. Metab. 99, E1627–E1634 (2014).
39. Oura, H. et al. A critical role of placental growth factor in the induction of
inﬂammation and edema formation. Blood 101, 560–567 (2003).
40. Luttun, A. et al. Revascularization of ischemic tissues by PlGF treatment, and
inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat.
Med. 8, 831–840 (2002).
41. Carmeliet, P. et al. Synergism between vascular endothelial growth factor and
placental growth factor contributes to angiogenesis and plasma extravasation
in pathological conditions. Nat. Med. 7, 575–583 (2001).
42. Yoo, S. A. et al. Role of placenta growth factor and its receptor ﬂt-1 in
rheumatoid inﬂammation: a link between angiogenesis and inﬂammation.
Arthritis Rheum. 60, 345–354 (2009).
43. Lijnen, H. R. et al. Impaired adipose tissue development in mice with inacti-
vation of placental growth factor function. Diabetes 55, 2698–2704 (2006).
44. Chappell, L. C. et al. Diagnostic accuracy of placental growth factor in women
with suspected preeclampsia: a prospective multicenter study. Circulation 128,
2121–2131 (2013).
45. Bauer, M., Goetz, T., Glenn, T. & Whybrow, P. C. The thyroid-brain interaction in
thyroid disorders andmooddisorders. J. Neuroendocrinol.20, 1101–1114 (2008).
46. Bergink, V. et al. Pre-eclampsia and ﬁrst-onset postpartum psychiatric episodes:
a Danish population-based cohort study. Psychol. Med. 45, 3481–3489 (2015).
47. Takahashi, H. C. A. Protein tyrosine phosphatases PTPδ, PTPσ, and LAR: pre-
synaptic hubs for synapse organization. Trends Neurosci. 36, 522–534 (2013).
48. Smith, D. J. et al. Genome-wide analysis of over 106,000 individuals identiﬁes 9
neuroticism-associated loci. Mol. Psychiatry 21, 749–757 (2016).
49. Broome, M. R., He, Z., Iftikhar, M., Eyden, J. & Marwaha, S. Neurobiological and
behavioural studies of affective instability in clinical populations: a systematic
review. Neurosci. Biobehav. Rev. 51, 243–254 (2015).
50. Insel, T. The NIMH research domain criteria (RDoC) project: precision medicine
for psychiatry. Am. J. Psychiatry 171, 395–397 (2014).
Ward et al. Translational Psychiatry  (2017) 7:1264 Page 9 of 9
Translational Psychiatry
